|
|
Imitrex (Sumatriptan succinate)
|
 |
Central nervous system agent
|
 |
Analgesic
|
 |
(Adults) Tablets: 25 to 100 mg; if ineffective, repeat at 2-hour intervals; max 200 mg/day. Spray: 5 to 20 mg; if necessary, repeat after 2 hours; max 40 mg/day. Injection: Max single dose 6 mg injected.
|
 |
Category C
|
 |
Warmth, cold, tingling, pressure, burning, numbness, tightness, flushing, chest symptoms, fatigue, dizziness, drowsiness, confusion, chest, jaw, or neck tightness. Bad taste, nausea with nasal spray. Contraindications: should not be given intravenously or to patients with ischemic heart disease.
|
Pregnancy Risk Categories defined:
A: Studies in pregnant women failed to show a risk to the fetus in the first
trimester - with no evidence of risk in the later trimesters.
B: Animals studies indicate no adverse effect to the fetus, but there are no adequate,
clinical studies in pregnant women.
C: Animal studies have shown an adverse effect on the fetus, but there are no adequate,
clinical studies in humans. Despite potential risks, the drug may be useful in pregnant
women.
D: There is evidence of risk to the human fetus, but the potential benefits of use in
pregnant women may be acceptable, despite potential risks.
X: Studies in animals or humans show fetal abnormalities, or adverse reaction reports
indicate evidence of fetal risk. Warning: the risks involved clearly outweigh any
potential benefit from using the drug in pregnant women, regardless of trimester.
NR: Not rated (i.e., no information available at this time as to the potential
risks or benefits).
|
| | |
If you want your friend to read or know about this article, Click here
 |
|
|
